The global saliva-based testing/screening market was estimated to be US$ 349.3 Million in 2022 and is expected grow at a CAGR of 8.3% between 2023 to 2032.
Saliva-based testing/screening is a non-invasive method of collecting and testing biological samples for various purposes, including medical diagnosis, drug testing, and disease screening. It involves collecting a small amount of saliva from an individual and analyzing it for the presence of specific biomarkers, such as viruses, bacteria, antibodies, or genetic material.
Saliva-based testing is an attractive alternative to other invasive and uncomfortable sampling methods, such as blood draws, and has gained increased attention during the COVID-19 pandemic as a convenient and reliable method for COVID-19 testing/screening.
Saliva-Based Testing/Screening Market Drivers
Adoption of saliva-based testing/screening is growing significantly in the future
Saliva-based testing/screening is an emerging diagnostic technology that offers a convenient, non-invasive, and cost-effective alternative to traditional blood-based tests.
The global saliva-based testing/screening market is being driven by several factors, including the increasing prevalence of infectious and chronic diseases, growing demand for non-invasive and rapid diagnostic tests, technological advancements in saliva-based testing devices and assays, and the need for convenient and scalable testing solutions due to the COVID-19 pandemic.
Additionally, increasing investments in research and development by key players and academic institutions, and a supportive regulatory environment for saliva-based testing/screening products are further contributing to the growth of the market.
The adoption of saliva-based testing/screening is expected to grow significantly in the coming years as the industry continues to develop new and innovative products that can detect multiple diseases and conditions simultaneously. The market is also likely to witness increased collaboration and partnerships between industry players and research organizations to develop more accurate and efficient saliva-based diagnostic technologies.
However, challenges such as the lack of standardization, variations in saliva composition, and the need for more robust validation studies need to be addressed to ensure the widespread adoption of saliva-based testing/screening. Overall, the future of the saliva-based testing/screening market is promising, and the technology has the potential to revolutionize disease diagnosis and monitoring.
Product type segmentation of Global Saliva-Based Testing/Screening Market
Saliva collection kits/device is the largest product type in the market
Based on product the market is segmented into Saliva collection kits/devices, Saliva nucleic acid purification kits, Saliva base detection kits, PCR based, and Rapid kits.
Among these, the saliva collection kits/devices segment is to be the largest as it forms the basis for all saliva-based testing. Saliva collection kits/devices are used to collect and preserve saliva samples, which can then be used for a variety of downstream assays and diagnostic tests.
As such, the demand for saliva collection kits/devices is expected to remain high across various application areas, including infectious diseases, cancer, and genetic testing.
While, in terms of the fastest-growing segment, it is the rapid kits segment. Rapid kits offer several advantages over traditional PCR-based assays, including faster turnaround times, lower costs, and easier sample collection and handling. With the ongoing COVID-19 pandemic and the need for rapid, scalable testing solutions, the demand for rapid saliva-based diagnostic tests is expected to surge.
Additionally, the development of more sensitive and specific rapid tests for a wide range of diseases and conditions is likely to drive growth in this segment in the coming years.
End-user segmentation of Global Saliva-Based Testing/Screening Market
Academic and research institute is the fastest-growing end-user in the market
Based on end-user, the market is segmented into Hospitals & Clinics, Diagnostic laboratories, Academic & research institutes, Biopharmaceuticals & CRO’s.
Among these, the hospitals and clinics segment is the largest as these institutions are the primary point of care for patients and are responsible for conducting diagnostic tests. Saliva-based tests offer several advantages over traditional blood-based tests, including ease of collection, reduced risk of exposure to infectious agents, and faster turnaround times.
Additionally, saliva-based tests can be conducted in a variety of settings, including hospitals, clinics, and home-based settings.
Academic and research institutes segment is the fastest-growing segment. Academic and research institutes play a critical role in the development and validation of new diagnostic technologies, including saliva-based tests. With the ongoing COVID-19 pandemic and the need for rapid, scalable testing solutions, academic and research institutions are actively collaborating with industry partners to develop and validate new saliva-based diagnostic technologies.
Additionally, academic and research institutions are increasingly using saliva-based tests for basic and translational research, including the identification of biomarkers for various diseases and conditions. This trend is likely to drive growth in the academic and research institutes segment in the coming years.
Regional trends of the Global Saliva-Based Testing/Screening Market
Asia-Pacific is a rapidly growing market for the market
Geographically, the global saliva-based testing/screening market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
Following are some of the major trends in these regions –
North America: North America is one of the most developed regions for the saliva-based testing/screening market. The region has a well-established healthcare infrastructure, high healthcare expenditure, and many diagnostic laboratories and hospitals. The COVID-19 pandemic has led to a significant increase in demand for saliva-based tests in the region.
Additionally, the region has been at the forefront of the development and adoption of new diagnostic technologies, including saliva-based tests. Furthermore, there has been significant investment by key players in the market to establish their presence in the region.
For instance, in January 2021, OraSure Technologies, Inc. received funding of USD 710,310 from the U.S. Department of Health and Human Services to develop a saliva-based test for COVID-19.
Europe: Europe is a mature market for the saliva-based testing/screening market, with a well-established healthcare infrastructure and a large number of diagnostic laboratories and hospitals. The region has also been at the forefront of the development and adoption of new diagnostic technologies, including saliva-based tests.
Additionally, the region has a supportive regulatory environment for the approval and commercialization of new diagnostic tests, which has driven the growth of the market. Furthermore, there has been significant investment by key players in the market to establish their presence in the region.
For instance, in December 2020, Lumos Diagnostics received CE-IVD marking for its SARS-CoV-2 RNA STAR Complete saliva-based test, enabling the commercialization of the test in Europe.
Asia-Pacific: Asia-Pacific is a rapidly growing market for the saliva-based testing/screening market, with a large and rapidly growing population driving demand for improved healthcare infrastructure and diagnostic technologies. The region has a large number of biopharmaceutical and contract research organizations (CROs) that are actively collaborating with academic and research institutions to develop and validate new diagnostic technologies, including saliva-based tests.
Additionally, the region has experienced significant outbreaks of infectious diseases in recent years, including COVID-19, which has led to increased investment in diagnostic testing infrastructure and technologies.
Furthermore, there has been a significant increase in public-private partnerships to develop and commercialize new diagnostic technologies. For instance, in October 2020, Xiamen Zeesan Biotech Co., Ltd. announced the launch of its CE-IVD marked COVID-19 saliva-based RT-PCR test in Europe and Asia.
Key players and market strategies:
Companies operating in the global saliva-based testing/screening market are adopting various growth strategies to expand their market share and improve their position in the market. Some of the key strategies adopted by these companies include partnerships, collaborations, and agreements, mergers and acquisitions, and product launches.
Many companies are forming partnerships and collaborations to enhance their product offerings and expand their geographic presence. For instance, in 2021, NeuMoDx Molecular and SalivaBio partnered to develop a fully automated saliva-based testing system for COVID-19.
Mergers and acquisitions are also a common growth strategy adopted by companies in the saliva-based testing/screening market. For example, in 2021, OraSure Technologies acquired Diversigen to enhance its molecular and microbiome analysis capabilities.
Product launches are also a key growth strategy in the market, with companies launching new and innovative products to meet the increasing demand for saliva-based testing/screening. For instance, in 2021, Oasis Diagnostics launched a new saliva collection device, which allows for easy and non-invasive collection of saliva for testing purposes.
Overall, companies operating in the global saliva-based testing/screening market are focusing on strategic collaborations, mergers and acquisitions, and product launches to improve their market share and stay ahead of the competition. These growth strategies are aimed at improving product offerings, expanding geographic presence, and enhancing overall competitiveness in the market.
Some of the biggest companies operating in the Global Saliva-Based Testing/Screening Market are BioChain Institute Inc., Biosynex SA, Cell Projects Ltd., Chembio Diagnostics, Inc., Creative Diagnostics, DNA Genotek Inc., Hologic, Invitek Molecular GmbH, Kyodo International, Inc., Mawi DNA Technologies LLC, NEOGEN Corporation, OraSure Technologies, Qiagen, Salimetrics, LLC., Sedia Biosciences Corporation, Spectrum Solutions, Thermo Fisher Scientific, Xiamen Zeesan Biotech Co., Ltd., Zymo Research Corporation, and many more.
Global Saliva-Based Testing/Screening Market Segmentation:
- Saliva collection kits/devices
- Saliva nucleic acid purification kits
- Saliva base detection kits
- PCR based
- Rapid kits
- Research use only
- Infection analysis/detection
- Genomic analysis
- Liquid biopsy
By End User:
- Hospitals & Clinics
- Diagnostic laboratories
- Academic & research institutes
- Biopharmaceuticals & CRO’s
- North America
- United States
- Rest of North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Rest of South America